Telehealth Patient Acquisition Cost: A Denominator-First Calculator

Quick answer

A telehealth patient acquisition cost number is not interpretable until the acquired unit is named. Spending $100,000 to generate 5,000 leads produces a different metric from spending the same amount to acquire 400 first fills or 250 subscribers retained to a defined checkpoint. Calling all three results CAC hides the funnel rather than explaining it.

The practical answer to the benchmark question is therefore: there is no meaningful telehealth CAC benchmark until the denominator, included costs, channel boundary, and measurement window are defined. This article provides a method and a reusable worksheet for constructing those definitions. It does not supply a universal industry-average number because the supplied evidence does not support one.

One public filing describes a platform that includes access to clinicians, digital prescriptions, pharmacy fulfillment, follow-up care, and nonprescription services. SEC filing Those functions represent distinct operational events. The useful acquisition metric is the one that matches the decision an operator is trying to make.

The Benchmark Question Is Missing a Denominator

Consider two fictional campaigns that each spend $120,000.

Campaign A generates 6,000 leads, producing a **$20 cost per lead**. Campaign B generates 540 first fills, producing a **$222.22 cost per first fill**. Those figures cannot be compared directly. The first measures the cost of creating an early expression of interest; the second measures the cost of reaching a later commercial event.

Cost per lead can help a media team compare hooks, audiences, or landing-page response. Cost per first fill can help an operator evaluate acquisition expense closer to realized service activity. Cost per retained subscriber can move the analysis closer to revenue durability. The reporting error is dropping the denominator and presenting every result as customer acquisition cost.

Every result should be labeled in full: cost per completed intake, fully loaded paid cost per booked consultation, blended cost per first fill, or another equally explicit description. The label should also identify the cohort and measurement window when those details could materially change the result.

What Telehealth CAC Means

The base equation is simple:

**Stage acquisition cost = acquisition expense assigned to a cohort ÷ new people in that cohort who reached the named stage.**

The analytical work lies inside three phrases: acquisition expense, assigned to a cohort, and named stage.

Acquisition expense may mean media spend alone, or it may include allocated creative, agency, affiliate, technology, platform, and promotional costs. A cohort may be defined by first attributed touch, lead creation, or another documented entry event. The named stage may occur immediately or weeks later. Each choice changes the result.

Visits, patients, orders, and subscriptions are not interchangeable. Teladoc reported completing 17.1 million telehealth visits through B2B and D2C channels in 2025, but a visit count is not automatically a count of newly acquired patients, subscribers, or paid-media conversions. SEC filing This is why the unit and distribution channel must remain attached to the metric.

Choose the Conversion Event Before Calculating

Use this denominator-first decision tree before opening an advertising dashboard:

These are optional, model-specific measurement points—not a mandatory universal sequence. An asynchronous workflow may have no booking event. Another care model may use a commercially relevant event other than a pharmacy fill. Mark a stage N/A when it does not apply.

Earlier events usually provide faster feedback and larger denominators. Later events usually sit closer to unit economics but require more time, cleaner identity reconciliation, and greater care around attribution.

Eligibility is a particularly important boundary. The calculator may count an operator-supplied eligibility event produced by an independent clinical process. It must never infer a missing decision, score a person's suitability, or encourage marketing teams to influence clinical judgment.

• **Are you diagnosing initial advertising response?** Use new leads, with a documented lead definition.
• **Are you evaluating whether interested people complete the information-gathering flow?** Use completed intakes.
• **Does the operating model include scheduling, and are you evaluating that handoff?** Use booked consultations.
• **Are you measuring how many acquired people were recorded as eligible by the existing clinical process?** Use eligible patients, but keep that decision outside marketing control.
• **Are you evaluating the cost of reaching an initial fulfilled commercial event?** Use one precisely defined event, such as pharmacy fulfillment or confirmed shipment.
• **Are you evaluating acquisition quality after time has passed?** Use subscribers retained to a named checkpoint.

The Denominator-First CAC Calculator

Use the blank worksheet below before calculating any result. A spreadsheet or interactive implementation can reproduce these fields directly.

1. Cohort and measurement inputs

2. Acquisition-expense inputs

Do not silently omit shared expenses. Select a consistent allocation driver—such as campaign usage, active days, documented labor, or spend share—and disclose it. Keep service-delivery costs out of the acquisition numerator if those costs will be deducted later in contribution margin.

3. Denominator and stage-cost inputs

For each applicable row:

**Paid stage acquisition cost = total explicitly included paid acquisition expense ÷ paid-attributed new people reaching the named stage.**

**Blended stage acquisition cost = total explicitly included acquisition expense across the selected channels ÷ new people from those channels reaching the named stage.**

Every generated label should include the cost scope, denominator, cohort, and measurement window. Example: **Fully loaded paid cost per first pharmacy-fulfilled order, January cohort, observed through May 31.**

4. Progression inputs

Calculate a progression rate only when both events are demonstrably nested, use the same people and cohort, and have a valid order in that operating model.

**Stage progression rate = people reaching the later applicable stage ÷ people reaching the preceding applicable stage.**

Do not calculate a rate when the events are not nested, the cohort definitions differ, or the sequence is not part of the operating model.

5. Contribution-margin and payback inputs

**Cohort contribution margin = net cohort revenue − variable costs assigned to serving the cohort.**

For payback, add one row for each reporting period:

**Contribution-margin payback occurs in the first mature period when cumulative cohort contribution margin equals or exceeds acquisition expense.**

6. Required validation flags

The calculator should suppress a result or display a visible warning when:

The calculator must not estimate missing clinical decisions or output a universal benchmark.

• Cohort dates, entry rule, attribution window, or observation end date are missing.
• The numerator and denominator use different cohorts or channel boundaries.
• A denominator is zero or below the operator's disclosed small-sample threshold.
• People have not been deduplicated under the stated rule.
• Shared acquisition costs remain unallocated.
• A stage is nonapplicable but has been treated as zero.
• A progression calculation uses events that are not demonstrably nested.
• Eligibility is missing an operator-supplied event from an independent clinical process.
• The full cohort has not reached the declared retention checkpoint.
• Revenue, refunds, or variable costs remain immature for the payback period.

Fictional Worked Example

The following assumptions apply only to this arithmetic illustration:

Using those assumptions:

These numbers are fictional illustrative arithmetic, not industry data or suggested targets.

Because this specific fictional model declares the events nested within one reconciled cohort, its progression rates can also be calculated: lead to completed intake is 40%, completed intake to booking is 50%, booking to recorded eligibility is 60%, recorded eligibility to first pharmacy-fulfilled order is 75%, and first fulfillment to day-90 retention is 66.7%.

Those rates locate where volume changes. They do not establish why it changed and should not be used to assign clinical causation. A model without booking, subscription, or pharmacy fulfillment should mark those stages N/A and calculate only its valid, nested transitions.

• 6,000 new leads produce a **$20 fully loaded paid cost per lead**.
• 2,400 completed intakes produce a **$50 fully loaded paid cost per completed intake**.
• 1,200 booked consultations produce a **$100 fully loaded paid cost per booked consultation**.
• 720 independently recorded eligible patients produce a **$166.67 fully loaded paid cost per eligible patient**.
• 540 first pharmacy-fulfilled orders produce a **$222.22 fully loaded paid cost per first pharmacy-fulfilled order**.
• 360 subscribers retained at day 90 produce a **$333.33 fully loaded paid cost per day-90 retained subscriber**.

Define the Cost Boundary

A denominator-first calculation still fails if the numerator is inconsistent.

At minimum, maintain two clearly labeled views. **Media-only stage cost** includes only spend purchased from advertising platforms. **Fully loaded paid acquisition cost** may add allocated creative production, agency management, affiliate commissions, acquisition technology, platform costs, and promotional subsidies. The exact policy can vary, but silent inclusion or exclusion makes comparisons unreliable.

For shared expenses, choose an allocation convention before viewing results. Creative production might be allocated by campaign usage, impression share, active days, or another consistently applied driver. Agency fees might be assigned by spend share or documented labor. No method is perfect; a stable, disclosed method is better than changing the rule after viewing performance.

Keep service-delivery costs out of the acquisition numerator if they are being used later in contribution margin. Otherwise, the same expense may be counted twice. Maintain a data dictionary that says where payment processing, clinical services, fulfillment, support, refunds, and promotional discounts appear.

Match the Metric to the Telehealth Business Model

Telehealth businesses should not be normalized solely by their homepages or acquisition channels. A systematic review of telehealth business models identifies interacting components including the value proposition, target customer, distribution channel, customer relationship, partnerships, resources, cost structure, and revenue model. peer-reviewed literature These components affect what the acquired unit represents and which expenses belong in the comparison.

One direct-to-patient company describes infrastructure spanning onboarding, consultation, prescription fulfillment, longitudinal care, an affiliated provider network, pharmacy capabilities, and acquisition-and-retention marketing. SEC filing That business description supports separating acquisition stages from retention; it does not establish that integration lowers CAC.

Another platform description includes access to clinicians, digital prescriptions, pharmacy fulfillment, follow-up care, and nonprescription services. SEC filing The supported fact is the breadth of the described experience, not a company-specific acquisition advantage.

B2B-distributed access and D2C paid-media acquisition also require different channel boundaries. An employer- or insurer-distributed member, a consumer lead, and a completed visit are different units. Readers comparing telehealth business models or direct-to-consumer telehealth companies should normalize the customer, channel, service event, cost structure, and revenue model before comparing acquisition economics.

Build a Cohort That Can Be Reconciled

Do not divide this month's spend by every conversion observed this month. That approach can combine new spending with outcomes generated by older campaigns while excluding later outcomes from the newest campaigns.

Instead, assign people to a fixed acquisition cohort using a documented entry rule. Then allow the cohort enough time to reach downstream milestones. Record the start and end dates, attribution window, expected conversion lag, channel, campaign, geography, and relevant care model.

Deduplicate people across devices, campaigns, and repeated submissions where the available data permits. Preserve the difference between a person and an event: one person can create several leads, book more than once, or generate multiple transactions. A new-patient denominator should not quietly become an event count.

Flag immature cohorts rather than filling missing outcomes with estimates. A day-90 retained-subscriber result cannot be complete before every included person has had the opportunity to reach day 90. Operators should also flag small denominators, unallocated costs, mixed geographies, changed intake flows, and material policy or pricing changes during the window.

Paid CAC, Blended Acquisition Cost, and Incrementality

Paid-channel CAC answers a narrow question: how much selected paid acquisition expense was associated with paid-attributed people reaching a named stage? Blended acquisition cost expands the numerator and denominator across explicitly included paid, owned, referral, partnership, and other channels.

Both views can be useful. Neither should impersonate the other.

Branded search may capture demand created elsewhere. Referral traffic may carry little directly assigned media expense. Partnerships may involve commercial terms outside an advertising platform. Owned audiences can change blended acquisition cost even when paid-channel economics have not changed.

Attribution also does not prove that an exposure caused an acquisition. Platform reporting, last-touch models, and multi-touch models distribute credit according to rules. Incrementality asks what would have happened without the exposure and requires a separate experimental or quasi-experimental design. Dashboards should label attributed results as attributed, not incremental, unless an appropriate test supports the stronger claim.

From First Fill to Retained-Subscriber Economics

A first fill is a clearer commercial milestone than a lead, but it still does not establish durable economics. Operators should compare acquisition expense with cohort contribution margin rather than gross revenue alone.

The implementation must define the commercial event precisely. Payment, pharmacy fulfillment, and confirmed shipment occur at different points and may produce different counts. The fictional example uses the first order marked fulfilled by the pharmacy; other implementations may select another approved event but must label it consistently.

**Cohort contribution margin = net cohort revenue − variable costs assigned to serving the cohort.**

Those variable costs may include clinical, fulfillment, payment, support, refund, and other service expenses according to the operator's accounting policy. The policy should be explicit and consistent.

**Contribution-margin payback occurs when cumulative cohort contribution margin equals or exceeds acquisition cost.**

Define the retention checkpoint before reading the results. Day 30, day 90, a billing cycle, or another interval may be operationally appropriate, but none should be presented as a universal default. Compare only fully matured cohorts at the same checkpoint.

One filing includes customer acquisition costs, customer retention, pricing decisions, offering mix, regulatory requirements, and operating efficiencies in its discussion of forward-looking statements and matters whose outcomes may differ from expectations. SEC filing That is verified context for viewing CAC alongside other operating considerations. It does not establish quantified causal relationships among them.

Why Cheap Leads Can Be Expensive

In a non-random internal sample, several long-form creatives opened with sensational specificity, borrowed authority, and unusually compressed outcome promises. **[Corpus note 1]** **[Corpus note 2]** **[Corpus note 3]**

In the same non-random internal sample, other creatives used shock, celebrity-style framing, humiliation, or relationship anxiety before introducing a simple claimed mechanism. **[Corpus note 4]** **[Corpus note 5]** **[Corpus note 6]**

These observations establish only that the patterns were present in the reviewed material. They provide no evidence of conversion, retention, revenue, compliance, profitability, or scale.

A testable marketing hypothesis is that a high-attention message could reduce cost per click or cost per lead while creating a weaker match with the intake experience. That hypothesis requires downstream cohort data; it is not a finding from the corpus.

In a non-random internal sample, offer sections also combined package anchoring, guarantees, scarcity, bonuses, and immediate checkout instructions. **[Corpus note 3]** **[Corpus note 6]** **[Corpus note 7]**

The sample does not show whether those elements changed conversion timing or order value. Same-day platform CAC remains incomplete without mature refund, contribution-margin, and retention data.

Editorial judgment: creative quality should be evaluated alongside downstream intent, claim quality, and message-to-landing-page consistency. Cheap traffic is not automatically efficient acquisition.

A Policy-Aware CAC Diagnostic

A lower reported CAC should trigger investigation, not automatic celebration. Add a nonclinical policy and quality layer beside the funnel report.

In a non-random internal sample, some health-related creatives combined confident causal stories, compressed timelines, institutional name-dropping, and permanent-result framing. **[Corpus note 8]** **[Corpus note 7]** **[Corpus note 9]**

This is an observed creative pattern, not a clinical evaluation and not evidence of conversion, retention, revenue, compliance, profitability, or scale.

For each campaign, track claim-review outcomes, creative rejections, account interruptions, complaint signals, refund behavior, and creative-to-landing-page consistency. Keep these operational measures separate from patient and clinical outcomes. A policy interruption can alter delivery and acquisition reporting without establishing anything about eligibility or care quality.

Review questions should include:

This framework is policy-aware business analysis, not legal advice or a compliance guarantee. Operators should use their own qualified marketing, legal, and clinical review processes.

• Does the landing page substantiate the advertising message?
• Are material qualifications visible before the conversion event?
• Did the campaign rely on urgency, authority, or implied certainty that the destination does not support?
• Were approvals and changes documented?
• Did refunds or complaints mature after the reporting window?
• Did a platform interruption distort spend or cohort volume?

The Telehealth CAC Reporting Template

Every recurring report should state:

Place applicable stage costs side by side. A strong report might show cost per lead, completed intake, booking, recorded eligibility, first fill, and retained subscriber in adjacent columns, with valid stage progression rates beneath them. That layout makes denominator changes visible instead of burying them in a single headline number.

When comparing campaigns or companies, require like-for-like definitions. If alignment is impossible, describe the difference and decline to rank the figures. Precision about uncertainty is more useful than a clean but misleading benchmark.

• Acquisition expense included and excluded
• Denominator and exact event definition
• Cohort entry rule and acquisition dates
• Attribution model and window
• Conversion-lag allowance or observation end date
• Paid, blended, or other channel boundary
• Care and distribution model
• Geography
• Deduplication method
• First-fill or first-commercial-event definition
• Retention checkpoint and cohort maturity
• Net-revenue treatment
• Variable-cost and refund treatment
• Contribution-margin payback method
• Applicable stages and stages marked N/A
• Whether progression events are demonstrably nested
• Known data gaps or changes during the period

The Final Operator Rule

Never ask whether telehealth CAC is high or low before asking what was acquired.

Name the event. Reconcile the cohort. Declare the numerator. Mark nonapplicable stages N/A. Separate paid attribution from blended acquisition and incrementality. Keep clinical eligibility outside marketing control. Then connect the later-stage result to mature contribution margin and retention.

That process will not create a universal telehealth CAC benchmark. It produces something more useful: an acquisition metric that can be audited, compared on consistent terms, and tied to the business decision it is supposed to inform.

Sources and Method Notes

Primary-source links appear beside the claims they support. Corpus notes describe a non-random internal sample and do not establish performance.

• **Corpus note 1.** Pattern observed in one item from Daily Intel's non-random Weight Loss transcript sample; observational context, not conversion evidence.
• **Corpus note 2.** Pattern observed in one item from Daily Intel's non-random Weight Loss transcript sample; observational context, not conversion evidence.
• **Corpus note 3.** Pattern observed in one item from Daily Intel's non-random Weight Loss transcript sample; observational context, not conversion evidence.
• **Corpus note 4.** Pattern observed in one item from Daily Intel's non-random Sexual Wellness transcript sample; observational context, not conversion evidence.
• **Corpus note 5.** Pattern observed in one item from Daily Intel's non-random Sexual Wellness transcript sample; observational context, not conversion evidence.
• **Corpus note 6.** Pattern observed in one item from Daily Intel's non-random Sexual Wellness transcript sample; observational context, not conversion evidence.
• **Corpus note 7.** Pattern observed in one item from Daily Intel's non-random Diabetes transcript sample; observational context, not conversion evidence.
• **Corpus note 8.** Pattern observed in one item from Daily Intel's non-random Diabetes transcript sample; observational context, not conversion evidence.
• **Corpus note 9.** Pattern observed in one item from Daily Intel's non-random Diabetes transcript sample; observational context, not conversion evidence.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Google helpful content guidance. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Telehealth marketing research library, Peptide Advertising on Google and TikTok: Policy Guide, Peptide Marketing Strategy: Clinic-First Direct Response, Telehealth Business Models: Cash-Pay, Subscription, and B2B, Telehealth Marketing Strategy: Click to Retention, and GLP-1 market research. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.